T11 P in GLP-1(9-36) primarily interacts with TM1, forming a hydrogen bond with L141 1.36b and hydrophobic contacts with Y145 1.40b , while T13 P interacts with the ECD by making two hydrogen bonds with S31 ECD and L32 ECD
The data lay this out: only 19% of firms with 200 or more workers include coverage for GLP-1 agonists when used for weight-loss in their largest health plan in 2025
However, the lack of human trials, quick degradability of liposomes and safety concerns of soy lecithin (a liposomal component) are barriers against its current use
The Journal of Molecular Endocrinology , 56(2), 127135
The cancer concern around BPC-157 is theoretical, based on its angiogenic properties
If youre going to sell me snake oil, make it believable snake oil. That said, I did follow the breadcrumb trail of these claims